Department of Stem Cell Transplantation and Cell Therapy, M.D. Anderson Cancer Center, Houston, Texas, USA.
Biol Blood Marrow Transplant. 2010 Jan;16(1 Suppl):S37-44. doi: 10.1016/j.bbmt.2009.10.018. Epub 2009 Oct 24.
Allogeneic hematopoietic stem cell transplantation remains the only curative option for myelodysplastic syndrome, but patients with this disease are often older and frail, and treatment-related mortality and morbidity is a major obstacle to be overcome. Treatment of MDS is likely to benefit from the major lines of investigation in the field of allogeneic transplantation, especially interventions postulated to decrease the morbidity of the procedure, such as less toxic preparative regimens. In this review we summarize current recommendations and controversies surrounding HSCT as well as integration of the novel therapeutic agents in the peritransplant period.
异基因造血干细胞移植仍然是骨髓增生异常综合征的唯一根治方法，但该疾病患者通常年龄较大且身体虚弱，与治疗相关的死亡率和发病率是需要克服的主要障碍。治疗 MDS 可能受益于同种异体移植领域的主要研究方向，特别是假设可以降低该程序发病率的干预措施，例如毒性较小的预处理方案。在这篇综述中，我们总结了围绕 HSCT 的当前建议和争议，以及在移植期间新型治疗药物的整合。
